Advertisements


Denali Therapeutics: Key Catalysts Coming Up For This Neurodegenerative Disease Pioneer

Denali Therapeutics: Key Catalysts Coming Up For This Neurodegenerative Disease Pioneer.....»»

Category: topSource: seekingalphaJun 12th, 2019

Denali Therapeutics announces ODD, Rare Pediatric Disease Designation for DNL310

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJun 11th, 2019

Gilead strikes deal with Nurix Therapeutics to tackle disease-causing proteins

Gilead Sciences Inc. is partnering with Nurix Therapeutics, a biotech working on drugs to destroy disease-causing.....»»

Category: topSource: marketwatchJun 19th, 2019

Is CymaBay Therapeutics’ Liver Disease Trial Sunk?

CymaBay Therapeutics shares were nearly halved early Tuesday after the company provided an update from its midstage study of seladelpar for the treatment of nonalcoholic steatohepatitis......»»

Category: blogSource: 247wallstJun 11th, 2019

CymaBay Therapeutics Plummets 40% Following Liver Disease Data

CymaBay Therapeu.....»»

Category: blogSource: benzingaJun 11th, 2019

$4.8 billion deal for gene therapy pioneer Spark Therapeutics delayed once more

The finish line for their proposed $4.8 billion deal is proving to be quite elusive for Roche and Spark Therapeutics. The companies announced Monday they have have each received a request for additional information and documentary material from the F.....»»

Category: topSource: bizjournalsJun 10th, 2019

Why Cara Therapeutics Could Rise Another 50%

Cara Therapeutics recently announced data from its late-stage trial in patients with chronic kidney disease. While there was a very positive reaction among investors, one analyst believes that this........»»

Category: blogSource: 247wallstMay 30th, 2019

What This Cara Therapeutics Late-Stage Study Could Mean for Chronic Kidney Disease

Cara shares jumped on Wednesday after the firm announced topline data from its late-stage trial in hemodialysis patients with moderate-to-severe chronic kidney disease-associated pruritus......»»

Category: blogSource: 247wallstMay 29th, 2019

Outlook Therapeutics: A Perfect Storm Of Positive Catalysts Driving Share Price Up

Outlook Therapeutics: A Perfect Storm Of Positive Catalysts Driving Share Price Up.....»»

Category: topSource: seekingalphaMay 20th, 2019

BioLineRx has multiple catalysts coming in 2019, says H.C. Wainwright

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallMay 14th, 2019

Biotech News Recap: Key NASH Readout Coming Up For CymaBay Therapeutics

Biotech News Recap: Key NASH Readout Coming Up For CymaBay Therapeutics.....»»

Category: topSource: seekingalphaMay 9th, 2019

Cyclerion Therapeutics: This Spinoff Has Multiple Readouts Coming Up, Concerns Remain

Cyclerion Therapeutics: This Spinoff Has Multiple Readouts Coming Up, Concerns Remain.....»»

Category: topSource: seekingalphaMay 9th, 2019

Denali Therapeutics reports Q1 EPS (41c), consensus (40c)

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallMay 8th, 2019

Biotech News Recap: Catalyst Pharmaceuticals Hit By Surprise From FDA, But Should Recover With Coming Catalysts

Biotech News Recap: Catalyst Pharmaceuticals Hit By Surprise From FDA, But Should Recover With Coming Catalysts.....»»

Category: topSource: seekingalphaMay 7th, 2019

Potentially Good News for Those Who Suffer From Pompe Disease

There may be some good news developing for those who suffer from Pompe Disease. Amicus Therapeutics, Inc. (NASDAQ: FOLD) has reported pre-clinical data from its Pompe disease gene therapy program and........»»

Category: blogSource: 247wallstApr 30th, 2019

Boston-based psychiatric drugmaker Karuna plans IPO

A Boston startup hoping to leverage the gastrointestinal and immune systems to create drugs for psychiatric disorders plans to launch an IPO in the coming months. Karuna Therapeutics has filed documents with the SEC to begin trading on the stock.....»»

Category: topSource: bizjournalsApr 29th, 2019

United Therapeutics is accused of unfairly blocking generic rival

The Maryland biotechnology company founded by a former satellite broadcasting executive to develop a treatment for her daughter’s rare disease is the target of a lawsuit......»»

Category: topSource: washpostApr 19th, 2019

Denali Therapeutics participates in a conference call with JPMorgan

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: personnelSource: nytApr 17th, 2019

Uber"s Coming Out Party: Personal Mobility Pioneer Or Overpriced Car Service Company?

Uber"s Coming Out Party: Personal Mobility Pioneer Or Overpriced Car Service Company?.....»»

Category: topSource: seekingalphaApr 16th, 2019

Insera Therapeutics ‘coming out of stealth mode’ after recent product approval

Sacramento-based Insera Therapeutics Inc. says it's ready to ramp up to commercialization now that it has approval to bring its medical device to Europe.  After nearly a decade developing a device for “minimally-invasive brain surgery” to rem.....»»

Category: topSource: bizjournalsApr 10th, 2019

Sorrento Therapeutics announces top line results from Parkinson"s disease study

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallApr 10th, 2019